Commentary|Videos|December 8, 2025
Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla
Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Robert Emmons, MD, FACP, of the University of Louisville, Joshua Brody, MD, of The Tisch Cancer Institute at Mount Sinai, and Javier Pinilla, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
A rituximab biosimilar has been approved by the FDA.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
The OncFive: Top Oncology Articles for the Week of 8/2
4
Five Under 5: Top Oncology Videos for the Week of 8/2
5